Autoimmune Market Forecast to 2014 (TA223)

Drive blockbuster revenue with autoimmune breakthroughs

The autoimmune market is proving that the era of the blockbuster is not dead.

Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.

Whether you're exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities — don't miss out!

From sales projections to clinical trial data to analysts' insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications — rheumatoid arthritis, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis and lupus — profiling 40+ drugs and nine leading autoimmune product manufacturers.

Delve into the data to:

• Learn how brands and drug classes have fared: where they've succeeded — and failed
• Show solid, objective evidence for your decision-making
• Keep track of the competition
• Get the latest on clinical trials
• Uncover potential business development opportunities